Extractables and leachables evidence breaks down when material knowledge, actual process contact, analytical data, toxicology, and product lifecycle live in separate files. A film extractables report does not by itself qualify a bioreactor bag; a stopper study does not support every drug product; an unidentified peak cannot be closed because it sits below an arbitrary reporting value.
Seal keeps the argument connected from material and component through worst-case exposure, study sample, raw analytical signal, compound identity, dose calculation, toxicological threshold, product risk, qualification decision, and every use that inherits the conclusion.
The product-contact map is the starting model
Product, process, stage, equipment, single-use assembly, filter, tubing, connector, gasket, lubricant, container closure, delivery device, packaging, cleaning agent, hold container, and transfer path define direct and indirect contact.
Material of construction, formulation, colorant, additive package, coating, adhesive, cure, sterilization, supplier, site, part revision, surface area, and assembly position preserve what can contribute compounds.
Actual-use conditions remain quantitative
Product or process fluid, solvent character, pH, ionic strength, surfactant, protein or lipid content, temperature, duration, surface-
Seal records ranges and time-varying stages instead of reducing a complex process to “product contact: yes.”
Material and supplier knowledge is versioned
Resin, polymer, elastomer, glass, metal, coating, formulation disclosure, controlled additives, processing aids, residual monomers, catalysts, inks, adhesives, supplier extractables, change notification, confidential disclosure, and regulatory declarations remain linked to the exact material revision.
Where composition is proprietary, the record can govern confidential evidence and unresolved knowledge without inventing completeness.
Risk assessment determines study depth
Patient route, daily dose, duration, population, product vulnerability, contact intensity, material complexity, process stage, downstream clearance, prior knowledge, manufacturing controls, detectability, and uncertainty drive risk.
The assessment differentiates manufacturing equipment, packaging, delivery systems, and combination products while retaining one portfolio view.
Study design starts from the intended conclusion
Screening, controlled extraction, simulation, migration, leachables, targeted monitoring, stability-
Protocol versions preserve test articles, lots, preparation, extraction vehicles, conditions, ratios, controls, replicates, analytical techniques, thresholds, identification expectations, criteria, and planned evaluation.
Bracketing is a governed scientific claim
Material formulation, supplier, component geometry, surface area, contact solution, pH, temperature, duration, sterilization, product route, daily dose, packaging configuration, and shelf life define comparability.
Seal records the worst-case factor by factor and shows every inherited use. An excluded configuration stays visible rather than disappearing from the study matrix.
Analytical evaluation thresholds are reproducible
Safety concern threshold, daily dose, units per day, concentration, sample preparation, dilution, extraction ratio, analytical uncertainty, response assumptions, and technique produce an analytical evaluation threshold or study-specific reporting threshold.
Every threshold retains formula, inputs, units, version, rationale, rounding, and approval. Recalculation after dose or presentation change identifies affected findings and conclusions.
Analytical methods preserve technique-specific evidence
GC-MS, LC-MS, ICP-MS, headspace GC, ion chromatography, spectroscopy, or other techniques retain instrument method, acquisition, source data, calibration, standards, blanks, system suitability, sample preparation, library, processing, integration, and audit trail.
Seal connects SDMS source files to normalized findings without pretending identification confidence is the same across techniques.
Each signal has an identification lifecycle
Retention time or index, accurate mass, isotope pattern, fragments, spectral match, elemental result, formula, candidate identities, authentic standard, confidence category, quantitation basis, response factor, detection frequency, blank correction, and analyst review evolve through investigation.
Unknowns remain first-class findings with mass, estimated concentration, confidence, open work, and decision impact.
Compound identity resolves across studies
Synonyms, salts, isomers, CAS or other identifiers, structure, formula, material source hypotheses, known additives or degradants, toxicological class, prior assessments, analytical standards, and linked findings form a controlled compound record.
The system avoids double-counting one compound under several laboratory names while preserving genuine ambiguity.
Exposure calculations connect to patient use
Measured or estimated concentration, product volume, maximum daily dose, dosing frequency, duration, body weight where relevant, leaching trend, shelf-life point, administration loss, and uncertainty calculate patient exposure.
Manufacturing-
Toxicological assessment is evidence, not a traffic light
Structure, genotoxicity, carcinogenicity, sensitization, irritation, reproductive or organ toxicity, route relevance, duration, population, read-across, permitted daily exposure or other threshold, uncertainty factors, local tolerance, data gaps, assessor qualification, literature, and conclusion remain versioned.
Acceptable, monitor, identify further, reduce exposure, control by specification, or unacceptable conclusions state their exact scope and assumptions.
Qualification ties evidence to the intended use
The decision identifies product-contact configuration, process or package, product, presentation, site, market, conditions, maximum exposure, supporting studies, compounds, unresolved unknowns, controls, restrictions, expiry or review, and approvers.
Supplier extractables can support the conclusion without becoming a blanket authorization.
Leachables monitoring follows product stability
Target compounds, unknown monitoring, batches, packaging configurations, orientations, storage conditions, pull points, analytical methods, thresholds, results, trends, degradation relationships, and specification or reporting decisions connect to the stability protocol.
The system can distinguish a transient manufacturing leachable from a compound that increases through shelf life.
Unexpected findings trigger bounded investigations
New peak, increased concentration, unknown above threshold, blank contamination, method artifact, standard issue, material mismatch, cross-
Impact traverses studies, compounds, materials, components, assemblies, products, batches, stability conclusions, distributed lots, filings, and supplier changes.
Change impact begins at the altered physical state
Material formulation, additive, resin source, supplier site, component geometry, surface treatment, sterilization, irradiation dose, process condition, contact time, product formulation, dose, route, package, shelf life, analytical method, threshold, or toxicological knowledge can affect qualification.
Where-used and bracketing identify the minimum new evidence without assuming every change requires a full repeat or no work.
Portfolio reuse remains controlled
Material knowledge, compound assessments, analytical standards, methods, supplier studies, extraction profiles, and qualified brackets can be reused across programs with explicit applicability.
Seal shows both the leverage and the dependency: a revised toxicological threshold or supplier formulation can identify every conclusion that reused it.
Where Seal is strongest
Seal is strongest at the seams between engineering, suppliers, analytical laboratories, toxicology, development, stability, manufacturing, packaging, quality, and regulatory. It makes E&L evidence reusable without disconnecting it from physical configurations and actual patient exposure.
Prove one difficult contact system end to end
The first implementation should follow one single-use flow path and final container closure through material versions, supplier disclosures, actual contact stages, risk assessment, controlled extraction, analytical methods, unknown identification, AET calculation, toxicological assessment, leachables stability, bracketing, qualification, supplier change, and impact.
Include one proprietary formulation, an unknown above AET, a blank contaminant, a compound with different route-specific thresholds, an unbracketed long contact, a dose change, and a changed film additive. The first authorization must show which exact uses are supported and every assumption they depend on.
